ACP-01 - Improving patient lives through autologous stem cell therapeutics

Our advanced therapy is clinically proven to improve circulation, cardiac performance and save limbs. Additionally, preliminary data shows ACP-01 improves cognitive function.

OUR MISSION

Transform patients' lives with an autologous (patient’s own) stem cell therapy that restores circulation to improve health.

OUR VISION

Lead the world in autologous (patient’s own) regenerative medicine: improve cardiac performance, peripheral circulation and cognitive function.

Identify Your Needs

Fill out a questionnaire to identify your treatment needs.

Book A Consultation​

Are you like one of the 498 end-stage “no-option” patients who qualified to be treated with ACP-01 under exemption? Or, are you at an earlier stage of the cardiovascular disease process, suffering from angina, ischemic cardiomyopathy, dilated cardiomyopathy, congestive heart failure, peripheral arterial disease, chronic limb threatening ischemia, or vascular dementia?

You may qualify to be treated under exemption, or as a participant in one of our seven studies, if you agree to be followed for up to one year.

We will discuss your condition and treatment options if applicable, and the relevant outcomes reported in our seven peer reviewed studies. That consultation is followed by a medical review of your healthcare records by a qualified physician. Given your condition, consideration of the exemption, inclusion and exclusion criteria, you may be offered a treatment.

Receive Your Treatment

Once scheduled, your personal concierge will coordinate all aspects of your tests, treatment and follow-up appointments. They will coordinate travel, accommodations, transportation to/from your treatment and ensure you are well taken care of throughout the process.

Hemostemix Transforming Lives - The Autologous Stem Cell Pioneer

Through seven clinical trials of ACP-01, in 318 subjects, for
Angina (24), Ischemic and Dilated Cardiomyopathy (41, 106, 54),
Peripheral Arterial Disease and Chronic Limb Threatening
Ischemia (6, 20, 67), Hemostemix has pioneered and scientifically
proven ACP-01 to be safe and statistically efficacious. ACP-01
increases circulation where the body signals that need. It
increases cardiac ejection fraction and exercise capacity. It saves
limbs from amputation.

Additionally, after one treatment, ACP-01 reversed the early onset
of vascular dementia. Mrs. L’s results have persisted for 10 years
and counting, which is why we are completing a Phase I clinical
trial.

Learn more about ACP-01 Treatment

Heart Treatment

Limb Treatment

Dementia Treatment

Clinically Proven. Globally Trusted.

Join us as a shareholder. Our journey is bringing ACP-01 to the 620 million who suffer from cardiovascular disease, including 236 million who have peripheral arterial disease, of whom 10% will degenerate into chronic limb threatening ischemia. Of the 30% of persons over 80 years who develop dementia, vascular disease is seen as a major contributing factor.

0

patients treated

0 %

of treated limbs were saved from amputation

0

Patents